Investor Relations

Avgo Biotech is EIS – SEIS compliant and approved.

We are currently looking for £150,000 to enable us to consolidate our commercial and technical position (capital is at risk –  investments can go down as well as go up).

Customer commitment will enable us to invest in commercial facilities and plant – with a target market entry of Q3 2022.

If you are interested in supporting AVGO, please contact:

Andrew Stacey

Mob: 07802 888742

email: andrew@recegg.com